semaglutide stop selling semaglutide shortage is over - Semaglutidecompounded near me semaglu The Shifting Landscape of Semaglutide: What You Need to Know About Sales and Compounded Versions

Semaglutidecompounded near me The conversation around semaglutide has been dominated by its effectiveness in managing type 2 diabetes and obesity, with the semaglutide shortage initially creating significant challenges for patients and healthcare providers. However, recent developments, particularly concerning the end of the semaglutide shortage on Feb 21, 2025, have led to significant changes in the availability and sale of both semaglutide injection products and their compounded versions2天前—Semaglutideis the active ingredient in Wegovy®and Ozempic®, offering powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with a broad range of indications including: obesity (Wegovy®), type 2 diabetes (Ozempic®), type 2 diabetes and chronic kidney disease .... The FDA removed semaglutide from the drug shortage list in February 2025, signaling a new era for this widely used medication.

For a period, a significant portion of the market for semaglutide and other GLP-1 medications consisted of compounded versions. These were often developed by compounding pharmacies to address the scarcity of FDA-approved injectables like Ozempic® and Wegovy®, which contain the active ingredient semaglutide2025年10月29日—The FDA ordered compounding pharmacies tostop producing and selling copies of GLP-1 injectable drugslike Ozempic, Wegovy, Mounjaro, and .... However, as the semaglutide shortage is over and the semaglutide shortage over has been officially declared, the U.S. Food and Drug Administration (FDA) has implemented new policies.2025年4月16日—Small compounders have untilApril 22to stop making and selling versions of Novo Nordisk's Wegovy; large compounders have until May 22. It ...

This shift means that compounding pharmacies can no longer make and sell semaglutide injections in the same capacity as beforeFDA's Removal of Semaglutide and the Evolving .... The FDA has instructed compounding pharmacies to stop when FDA-approved versions are readily available. State-licensed compounding pharmacies (503A businesses) were given a deadline of April 22 to stop selling semaglutide injection products that were not considered to be in compliance with new regulations. Similarly, larger compounding entities were given until May 22 to stop producing and dispensing compounded semaglutide.2天前—Semaglutideis the active ingredient in Wegovy®and Ozempic®, offering powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with a broad range of indications including: obesity (Wegovy®), type 2 diabetes (Ozempic®), type 2 diabetes and chronic kidney disease ... This directive effectively means these cheaper, off-brand versions of semaglutide and related GLP-1 drugs must be out of the market by Thursday, May 21, 2025, for larger compounders.

The FDA’s stance is rooted in ensuring patient safety and access to officially approved medications. The agency has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled "for research purposes.2025年2月22日—FDA says state-licensed compounding pharmacies (503A businesses)have until April 22to stop selling semaglutide injection products “that are ..." Companies like Semaspace have already faced scrutiny and had to shut down its websiteSemaglutide injections will no longer be ... - FOX 10 Phoenix. Furthermore, the FDA has directly warned online vendors to stop selling unapprovedsemaglutide-based productsNow that thesemaglutide shortage is over, compounded GLP-1s are being phased out. Will compounded GLP-1s disappear completely? Pharmacists don't think so.. A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs that many patients previously relied on.Are Compounded GLP-1s Going Away? Not Entirely

This regulatory action has had a direct impact on some telehealth platforms. For instance, Hims & Hers has been a prominent provider of compounded semaglutide services.2025年11月18日—The FDA declared thesemaglutide shortage over. Because of this, compounded semaglutide is only available in certain situations. Following the FDA's clarification and the resolution of the shortage, Hims said it would stop selling the pills in some instances. Despite the "grace period" for manufacturers to stop producing and selling compounded tirzepatide ending, and the federal deadline for off-brand GLP-1 drugs, some platforms are navigating the new landscape differently. While Hims & Hers warned it may stop selling compounded weight-loss products, reports indicate some online platforms have confirmed they will continue offering compounded semaglutide to eligible patients despite upcoming FDA restrictionsCompounded Versions Of Ozempic Now Restricted By FDA. For example, one report states Hims & Hers has confirmed it will keep offering compounded semaglutide to eligible patients despite the upcoming FDA restrictions. This suggests a nuanced application of the regulations or ongoing adjustments by these companies. However, Hims & Hers did not respond to a query about whether it would continue selling compounded semaglutide injections on its website, indicating potential uncertainty or ongoing strategic decisions. In a notable instance, Hims & Hers pulls copycat weight-loss pill after legal threats, highlighting the pressure from pharmaceutical manufacturers.FDA clarifies policies for compounders as national GLP-1 ...

The implications of the FDA's decision are far-reaching2026年2月7日—Hims & Hers did not respond to a Reuters query about whether it would continuesellingcompoundedsemaglutideinjections on its ‍website.. The end of the shortage and the subsequent restrictions on compounded versions mean that patients may find it more challenging to obtain affordable weight-loss medications. The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain affordable weight loss medicationsNow that thesemaglutide shortage is over, compounded GLP-1s are being phased out. Will compounded GLP-1s disappear completely? Pharmacists don't think so.. While some pharmacies that were selling these compounded drugs have had to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, the market is still adaptingFDA removes semaglutide from drug shortage list.

It's important to distinguish between FDA-approved medications and compounded versions. Compounded "semaglutide" is not FDA-approved, and while some continue to seek it, the regulatory environment is clearly shifting towards prioritizing the officially sanctioned semaglutide products. The FDA's primary goal is to ensure that patients seeking treatments for conditions like obesity and type 2 diabetes have access to safe and effective medications, which are the FDA-approved semaglutide in its branded forms such as Wegovy® (for obesity) and Ozempic® (for type 2 diabetes and chronic kidney disease), and Mounjaro (which contains tirzepatide, another GLP-1 receptor agonist).

The era of widespread availability of compounded semaglutide is drawing to a close. As the semaglutide shortage is over, patients seeking treatment should consult with their healthcare providers to discuss all available options, including FDA-approved semaglutide and its therapeutic indications. The focus is now on ensuring continued access to legitimate and safe treatment for all patients. The FDA's removal of semaglutide from the drug shortage list has marked a significant shift, impacting pharmacies and patients alike, and forcing a re-evaluation of how these powerful medications are accessedThe FDA has removed semaglutide injection products ....